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OBJECTIVE — Microalbuminuria is associated with cardiovascular mortality, particularly
among individuals with type 2 diabetes, but the mechanisms underlying this association are not
completely understood. Microalbuminuria is known to be associated with cardiovascular auto-
nomic dysfunction (C-AD), and C-AD in turn is associated with cardiovascular mortality. The
purpose of this study, therefore, was to investigate whether C-AD can explain the relationship
between microalbuminuria and cardiovascular mortality.
RESEARCH DESIGN AND METHODS — We studied 490 individuals from a popula-
tion-based cohort of individuals aged 50–75 years who were followed for a median period of
13.6 years. Microalbuminuria was deﬁned as an albumin-to-creatinine ratio 2.0 mg/mmol in
an early-morning spot-urine sample. Ten parameters reﬂecting different aspects of cardiovascu-
larautonomicfunctionweremeasuredandcompiledintoatotalscoreofC-AD(meanofseparate
zscores).TheassociationbetweenC-ADandmicroalbuminuriawasestimatedbymultiplelinear
regression, and relative risks (RRs) for cardiovascular mortality were estimated by Cox propor-
tional hazards analyses.
RESULTS — After adjustments for age, sex, glucose tolerance status, and other risk factors,
C-AD was associated with microalbuminuria (0.16 [95% CI 0.01–0.33]), and both mi-
croalbuminuria (RR 2.09 [1.07–4.08]) and C-AD (1.74 [1.04–2.89]) were associated with
cardiovascular mortality. These associations did not change after further mutual adjustment for
C-AD (2.13 [1.09–4.17]) or microalbuminuria (1.76 [1.05–2.94]), respectively.
CONCLUSIONS — Both microalbuminuria and C-AD are independently associated with
cardiovascular mortality, and the excess mortality attributable to microalbuminuria cannot be
explained by C-AD.
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M
icroalbuminuria is associated
with an increased risk of cardio-
vasculardiseaseandmortality(1).
This association is independent of other
known cardiovascular risk factors such as
hypertension, dyslipidemia, obesity,
smoking, and impaired renal function
(1,2). Several mechanisms, notably endo-
thelial dysfunction and low-grade inﬂam-
mation,havebeenproposedtoexplain,at
least in part, the increased risk of cardio-
vascular mortality in individuals with mi-
croalbuminuria (3). Cardiovascular
autonomic dysfunction (C-AD) could
potentially constitute another such
mechanism.
Indeed, we as well as others have pre-
viously shown that C-AD is associated
with microalbuminuria, especially in in-
dividuals with impaired glucose metabo-
lism (IGM) and type 2 diabetes (4–6).
Two proposed mechanisms explaining
this association are, ﬁrst, a disturbance in
glomerular arteriolar autoregulation,
which in turn may result in an inability to
counteract glomerular hypertension (7),
and, second, a reduced drop in nightly
blood pressure due to C-AD, both of
which may result in microalbuminuria
(8). In addition, C-AD is associated with
cardiovascular mortality (9,10) and can
potentially link microalbuminuria to car-
diovascular mortality by arrhythmogenic
or atherogenic effects, for example, by
promotingvascularcalciﬁcationandarte-
rial stiffness (11).
In view of these considerations, we
investigated, in a prospective cohort
study, whether C-AD can explain the re-
lationship between microalbuminuria
and cardiovascular mortality or, alterna-
tively, whether both microalbuminuria
and C-AD are independently associated
with cardiovascular mortality. These hy-
potheses have never been investigated in
the general population and could have
clinical relevance because the ﬁrst hy-
pothesis suggests that C-AD should be
targeted to decrease mortality risk in in-
dividuals with microalbuminuria and,
conversely, the second hypothesis sug-
gests that both microalbuminuria and
C-AD can be used for estimating the risk
of cardiovascular mortality.
RESEARCH DESIGN AND
METHODS— We used data from the
Hoorn Study, a population-based cohort
study on glucose metabolism and other
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Caucasian population, which has been
described in detail previously (12). In
brief, men and women aged 50–75 years
were randomly selected from the popula-
tion register of the town of Hoorn, the
Netherlands; 2,484 subjects participated
(response rate 71%). Baseline examina-
tions were conducted from October 1989
until February 1992. All subjects had a
75-g oral glucose tolerance test, except
those in whom type 2 diabetes had previ-
ously been diagnosed. An extensive met-
abolic and cardiovascular investigation
was performed in an age-, sex-, and glu-
cose tolerance–stratiﬁed, random sub-
sample of 631 participants (89% of those
invited), which is used in the present
study (12).
Participants without representative
urine samples available (n  45) and/or
who did not complete at least 7 of the 10
autonomic function tests (n  31), had a
history of neurological disease (n  5),
and were using ACE inhibitors (n  33)
and/or drugs known to inﬂuence auto-
nomic nerve function (namely antipar-
kinson drugs, phenytoin, antihistamines,
or parasympatholytic, parasympathomi-
metic, and sympathomimetic drugs) (n 
49) were excluded from the analyses. The
present study, therefore, consisted of 490
individuals:305withnormalglucoseme-
tabolism, 71 with IGM (including those
with impaired fasting glucose and/or im-
paired glucose tolerance), and 114 with
type 2 diabetes.
The Hoorn Study was approved by
the ethical review committee of VU Uni-
versity Medical Centre, Amsterdam, the
Netherlands. Informed consent was ob-
tained from all participants.
Baseline measurements
Urinary albumin concentration was mea-
sured in a ﬁrst voided sample by rate
nephelometry (Array Protein System,
BeckmanCoulter,Galway,Ireland)witha
detectionthresholdof6.2mg/l(intra-and
interassay coefﬁcients of variation of 5
and 8%, respectively). Urinary creatinine
was measured with a modiﬁed Jaffe ´
method. Microalbuminuria was present if
the albumin-to-creatinine ratio (ACR)
was in the range of 2.0–30 mg/mmol (5).
The average value of the ACR was used if
two representative samples (n  154)
were available. Excluding subjects with
an ACR 30 mg/mmol (i.e., macroalbu-
minuria, n  4) did not materially affect
anyoftheresults,whicharethereforepre-
sented for the entire group.
Cardiovascular autonomic function
tests were performed as described in de-
tail elsewhere (9). In brief, participants
were asked to refrain from smoking and
drinking coffee for at least 2 h before the
assessments. A light meal 1 h before the
measurements was allowed. Tests took
place between 8:30 A.M. and 4:00 P.M.i na
quiet location with room temperature of
19–22°C after a resting period of at least
10 min. Ten parameters of cardiac auto-
nomic function were derived from the
R-R interval and ﬁnger systolic blood
pressure (SBP) continuous recordings by
a computerized data analyses system de-
veloped locally by the Department of
Medical Physics, VU University, Amster-
dam, the Netherlands (13). Tests were
performed under three conditions: dur-
ing spontaneous breathing over 3 min in
the supine position (mean of all normal
to normal R-R intervals [MeanNN], SD
of all normal to normal R-R intervals
[SDNN], low-frequency [LF] power, high-
frequency [HF] power, and LF/(LF 
HF)), during six deep breaths over 1 min
in the supine position (expiration-
inspiration [EI] difference and baroreﬂex
sensitivity [BRS]), and during an active
changefromlyingtostanding(SBPdiffer-
ence, R-R interval maximum [RRmax],
and R-R interval maximum divided by
minimum [RRmax/min]) (for further ex-
planation of measurements, see supple-
mentary Table A1, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc08-1544/DC1). We
thus obtained results in four tests that
reﬂect heart rate or blood pressure
changes due to certain “maneuvers,” in
this case deep breathing or standing up
(i.e., EI difference, RRmax,R R max/min,
and SBP difference) (14), ﬁve tests of
spectral analyses of heart rate variability
(HRV) [i.e., MeanNN, SDNN, LF power,
HF power, and LF/(LF  HF)] (15), and
one BRS measurement (16). In addition,
thesetestsweregroupedintothoserepre-
senting predominantly parasympathetic
(i.e., EI difference, RRmax, and HF
power), sympathetic (i.e., SBP differ-
ence), or both functions (i.e., Mean-NN,
SDNN, LF power, LF/(LF  HF), BRS,
and RRmax/min) (15,16).
BMI, waist-to-hip ratio (WHR), SBP
and diastolic blood pressure (DBP), levels
of fasting plasma glucose; A1C; insulin;
total, HDL, and LDL cholesterol; triglyc-
erides; creatinine; and smoking status
were measured as described elsewhere
(5,9,12). Glomerular ﬁltration rate was
estimated by the short Modiﬁcation of
DietinRenalDiseaseequation.Hyperten-
sion was deﬁned as SBP 140 mmHg
and/orDBP90mmHgand/ortheuseof
antihypertensive drugs. Prior cardiovas-
culardisease(CVD)wasdeﬁnedwhenin-
dividuals had (any of the following): a
history of myocardial infarction, abnor-
malities on a resting electrocardiogram
(Minnesota codes 1.1–1.3, 4.1–4.3, 5.1–
5.3, or 7.1), previous coronary bypass
surgery or angioplasty, peripheral arterial
bypass, or nontraumatic amputation, or
an ankle-brachial index of 0.9 in either
leg.
Follow-up
Data on the participants’ vital status up to
1 January 2005 were collected from the
mortality register of the municipality of
Hoorn.Informationoncauseofdeathwas
extracted from the medical records of the
general practitioners and the local hospi-
tal and coded according to the ICD-9.
Cardiovascular mortality, including sud-
den death, was deﬁned by ICD-9 codes
390–459 and 798. Information on cause
of death could not be obtained for 20 of
the deceased individuals. All subjects
were followed until death or end of fol-
low-up, at which time they were
censored.
Statistical analyses
Baselinecharacteristicsbetweensurvivors
and nonsurvivors were compared with
the use of Student’s t or 
2 tests. We com-
puted z scores ([individual’s observed
valuepopulationmean]/SD)foreachof
the 10 measurements of C-AD. All z
scores (except SBP difference) were in-
verted and averaged into a total score
(“C-ADtotalscore”),sothathighervalues
reﬂect greater C-AD.
The association between microalbu-
minuria and C-AD total score was inves-
tigated with multiple linear regression
analyses. Kaplan-Meier survival curves
were plotted for cardiovascular mortality
among individuals with normoalbumin-
uria versus microalbuminuria and simi-
larly across tertiles of the C-AD total
score, and differences between groups
were tested with a log-rank test. Cox pro-
portional hazards regression models were
used to calculate the crude and adjusted
relativerisks(RRs)andrespective95%CI
of microalbuminuria (versus normoalbu-
minuria) and of the C-AD total score (per
SD[0.605]increase)forcardiovascular
and all-cause mortality. Two-sided P 
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cant. All analyses were performed with
SPSS (version 15.0).
RESULTS— Subjects excluded from
the analyses (n  141) were older, more
oftenhadtype2diabetes,andhadaworse
risk proﬁle than the subjects included
(n  490) (data not shown). Median du-
ration of the follow-up was 13.6 (range
0.52–15.19) years. During the follow-up
period, 141 (28.8%) participants died, of
whom 53 (37.6%) died of CVD. At base-
line, individuals who died had a worse
C-AD total score, more often had mi-
croalbuminuria and were older, more of-
tenweremenandhadtype2diabetesand
hypertension, and had a higher A1C and
WHR as compared with the survivors
(Table 1).
Association between
microalbuminuria and C-AD
C-AD total score was associated with mi-
croalbuminuria(0.33[95%CI0.16–
0.51]) (Table 2, model 1). After
adjustmentforpotentialconfoundingfac-
tors, C-AD total score was still borderline
associated with microalbuminuria (0.16
[0.01 to 0.33]) (Table 2, model 3).
Comparable results were obtained when
tests were combined on the basis of their
methodology or on the part of the auto-
nomic nervous system they predomi-
nately represent. All individual C-AD
tests, except LF/(LF  HF), were posi-
tively associated with microalbuminuria
(although not all statistically signiﬁcantly
so) (data not shown).
Association of microalbuminuria
and C-AD total score with
cardiovascular and all-cause
mortality
Bothmicroalbuminuria(RR3.49[95%CI
1.87–6.53]) and C-AD total score (2.54
[1.60–4.04]) were associated with car-
diovascular mortality (Table 3, model 1;
Table 1—Baseline characteristics of survivors versus nonsurvivors
Survivors
Nonsurvivors
All-cause
mortality
Cardiovascular
mortality
n 349 141 53
Age (years) 62.4  6.8 67.1  6.4* 67.7  6.7*
Sex (% men) 43.6 53.9* 50.9
Glucose tolerance status
NGM 66.5 51.8 43.4
IGM 14.0 15.6 17.0
Type 2 diabetes 19.5 32.6* 39.6*
A1C (%) 5.7  1.1 6.2  1.4* 6.4  1.6*
SBP (mmHg) 136.2  18.5 142.8  19.6* 147.2  21.6*
DBP (mmHg) 82.0  9.3 83.3  11.2 84.4  10.8
Use of blood pressure–lowering drugs (%)† 20.9 31.9* 32.1*
Hypertension (%) 46.4 65.2* 69.8*
History of CVD (%) 19.8 27.0 30.2
Ever smokers (%) 59.6 71.6* 73.6
WHR 0.90  0.08 0.94  0.08* 0.95  0.08*
BMI (kg/cm
2) 26.8  3.7 27.2  3.9 27.4  3.8
Serum creatinine (	mol/l) 89.5  16.1 95.0  23.0* 97.6  30.6
eGFR (ml/min) 69  11 66  13* 64  15*
Cholesterol (mmol/l) 6.61  1.13 6.73  1.31 6.86  1.19
HDL cholesterol (mmol/l) 1.31  0.37 1.26  0.34 1.23  0.31
LDL cholesterol (mmol/l) 4.51  0.99 4.60  1.13 4.77  1.05
Use of lipid-lowering drugs (%) 1.7 1.4 1.9
Triglycerides (mmol/l) 1.50 (1.10–2.10) 1.70 (1.20–2.40)* 1.80 (1.25–2.40)
EI difference (ms) 162 (107–237) 131 (83–213)* 113 (79–183)*
RRmax (ms) 254  96 217  88* 223  91*
RRmax/min 1.27  0.16 1.19  0.14* 1.21  0.13*
HF power (ms
2) 183 (85–438) 151 (67–363)* 145 (77–330)
LF power (ms
2) 239 (123–525) 160 (68–390)* 152 (63–307)*
LF/(LF  HF) 0.56  0.19 0.52  0.21 0.50  0.21*
BRS (ms/mmHg) 9.01  4.96 7.91  4.20* 7.84  4.14
SDNN (ms) 36  16 33  19* 32  19
MeanNN (ms) 966  147 927  156* 935  157
SBP difference (mmHg) 6.42  14.82 6.32  15.17 6.45  16.51
C-AD total score 0.08  0.58 0.22  0.61* 0.22  0.65*
Microalbuminuria (%) 7.7 16.3* 24.5*
Dataarepresentedasfrequencies(%),meansSD,ormedians(interquartilerange).Foradetailedexplanationofautonomicfunctiontests,seesupplementaryTable
A1.*P0.05vs.survivors.†Theseincludediuretics,
-blockers,-blockers,calciumchannelblockers,andotherbloodpressure–loweringdrugsbutexcludeACE
inhibitors (because subjects using these drugs were excluded from the analyses). eGFR, estimated glomerular ﬁltration rate; NGM, normal glucose metabolism.
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ated after adjustment for age, sex, and
glucose tolerance status (GTS) (2.23
[1.16–4.29] and 1.81 [1.11–2.94], re-
spectively; model 2). Further adjustment
for other cardiovascular risk factors only
slightly further attenuated these RRs
(model3),andwhentheC-ADtotalscore
or microalbuminuria was added to these
models, the RR attributable to microalbu-
minuria remained practically unchanged
and both microalbuminuria (2.13 [1.09–
4.17]) and C-AD total score (1.76 [1.05–
2.94]) were independently associated
with cardiovascular mortality (model 4).
BothmicroalbuminuriaandC-ADtotal
score were also associated with all-cause
mortality(Table3,model1).However,after
adjustmentforage,sex,GTS,andothercar-
diovascular risk factors, microalbuminuria
(RR 1.33 [95% CI 0.83–2.13]), in contrast
toC-ADtotalscore(1.52[1.11–2.09]),was
notindependentlyassociatedwithall-cause
mortality (model 3).
Additional analyses
The associations described above were also
investigatedbyexaminingautonomicfunc-
tion tests combined on the basis of their
methodology or on the part of the auto-
nomic nervous system they predominantly
represent (supplementary Table A2, avail-
able in an online appendix). These addi-
tional analyses showed that overall all
different groups of tests were associated
with increased mortality risk, that these as-
sociationswereattenuatedwhenfurtherad-
justed for age, sex, GTS, and other risk
factors; and that none of the speciﬁc group
of tests explained the association between
microalbuminuria and mortality.
The associations reported in Table 3
did not materially change after additional
adjustment for use of lipid- or blood pres-
sure–lowering drugs and the presence of
leukocytes in urine (tested by microscopy
and scored as positive whenever there were
more than ﬁve leukocytes per high-power
ﬁeld)orwhenthedichotomousvariablehy-
pertension used in those models was re-
placed by either SBP or pulse pressure (a
marker of arterial stiffness) or when analy-
ses were adjusted for prior coronary heart
disease instead of prior CVD (data not
shown). Finally, we found no evidence of
effect modiﬁcation by GTS in the associ-
ation between cardiovascular mortality
and C-AD total score or microalbumin-
uria (Pinteraction  0.4 in both cases).
CONCLUSIONS — In this prospec-
tive study we found that both microalbu-
minuria and C-AD (estimated from the
meanof10standardizedtests)wereinde-
pendently associated with cardiovascular
mortalityinacohortofelderly,Caucasian
subjects with and without diabetes.
Therefore, C-AD does not explain why
microalbuminuria is related to cardiovas-
cular mortality in either the general pop-
ulation or in diabetic subjects.
Recently, HRV was found not to pre-
dict the decline of GFR but was indepen-
dently associated with cardiovascular
mortality in middle-aged type 1 diabetic
subjects with overt nephropathy (17). In
another study, investigating the indepen-
dent predictive role of GFR, microalbu-
minuria, and cardiovascular autonomic
neuropathy showed the latter to also be
associated with all-cause and cardiovas-
cular mortality in subjects with diabetes
(18). These ﬁndings are in line with those
reported herein. Hitherto, no other pro-
spective studies examining the relation of
microalbuminuriaandC-ADwithcardio-
vascular mortality have been reported.
Table 2—Association between microalbuminuria and C-AD
Model* † 95% CI P
C-AD total score 1 0.33 0.16 to 0.51 0.001
2 0.21 0.04 to 0.38 0.016
3 0.16 0.01 to 0.33 0.067
C-ADmaneuvers 1 0.34 0.15 to 0.53 0.001
2 0.17 0.01 to 0.35 0.061
3 0.12 0.07 to 0.30 0.209
C-ADBRS 1 0.40 0.08 to 0.71 0.014
2 0.23 0.08 to 0.54 0.149
3 0.21 0.11 to 0.53 0.194
C-ADHRV 1 0.31 0.12 to 0.51 0.001
2 0.22 0.03 to 0.41 0.025
3 0.16 0.04 to 0.35 0.110
C-ADparasympathetic 1 0.45 0.22 to 0.69 0.001
2 0.28 0.05 to 0.51 0.017
3 0.23 0.01 to 0.46 0.055
C-ADsympathetic 1 0.14 0.18 to 0.44 0.394
2 0.13 0.19 to 0.44 0.433
3 0.11 0.22 to 0.44 0.503
C-ADboth 1 0.32 0.14 to 0.49 0.001
2 0.23 0.06 to 0.41 0.001
3 0.18 0.01 to 0.36 0.041
*Model 1: univariate analysis; model 2: adjusted for sex, age, and GTS; model 3: model 2 plus adjustments
for hypertension, WHR, estimated glomerular ﬁltration rate, LDL, HDL, triglycerides, smoking, and prior
CVD. † indicates the difference in C-AD score between individuals with microalbuminuria vs.
normoalbuminuria.
Table 3—Association of microalbuminuria or C-AD with cardiovascular and all-cause
mortality
Model*
RR (95% CI)†
Cardiovascular
mortality
All-cause
mortality
Microalbuminuria 1 3.49 (1.87–6.53) 2.12 (1.36–3.21)
2 2.23 (1.16–4.29) 1.46 (0.92–2.31)
3 2.09 (1.07–4.08) 1.32 (0.83–2.12)
4 2.13 (1.09–4.17) 1.33 (0.83–2.13)
C-AD total score 1 2.54 (1.60–4.04) 2.11 (1.58–2.81)
2 1.81 (1.11–2.94) 1.62 (1.20–2.20)
3 1.74 (1.04–2.89) 1.52 (1.11–2.08)
4 1.76 (1.05–2.94) 1.52 (1.11–2.09)
*Model 1: univariate analysis; model 2: adjusted for sex, age, and GTS; model 3: model 2 plus adjustments
for hypertension, WHR, estimated glomerular ﬁltration rate, LDL, HDL, triglycerides, smoking and prior
CVD; model 4: model 3, with additional adjustment for, respectively, C-AD or microalbuminuria. †RR of
microalbuminuria vs. normoalbuminuria or per SD (0.605) increase in C-AD total score.
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croalbuminuria and C-AD with cardio-
vascular mortality reported herein
indicates that they are linked to cardio-
vascular mortality by different biological
pathways. Several mechanisms linking
C-AD to cardiovascular mortality have
been proposed (e.g., QT interval prolon-
gation and silent myocardial ischemia)
(19). Microalbuminuria may be linked to
CVD by a common pathophysiological
process (such as endothelial dysfunction
or chronic low-grade inﬂammation) (3).
However, the possibility that microalbu-
minuria reﬂects the presence of a set of
undiscovered factors that are causally re-
lated to CVD remains to be further eluci-
dated. Our study shows that C-AD is an
unlikely candidate in this regard.
Microalbuminuria is an established
risk indicator for CVD. Furthermore, ag-
gressive treatment of microalbuminuria
by inhibiting the renin-angiotensin-
aldosteronesystemhasbeenshowntode-
crease renal and cardiovascular risk in
individuals with diabetes (20). There is
some evidence that C-AD is also a useful
risk indicator for CVD, especially in sub-
jects at high risk (type 2 diabetes, hyper-
tension, or prior CVD) (9,21), and this
study reinforces that observation. How-
ever, whether the improvement in C-AD,
e.g., with exercise training or blood pres-
sure– or lipid-lowering drugs (22–24),
leadstoabetterprognosisisunknown.In
our study, additional adjustment for use
of -blockers or lipid-lowering drugs had
no effect on the associations reported.
Therefore, the clinical relevance of treating
C-ADinthegeneralpopulationremainsun-
clear and needs to be further examined.
The strengths of our study are the rel-
atively large, truly population-based and
prospective design with a long follow-up
period.Inaddition,wecharacterizedsub-
jects’ C-AD as comprehensively as possi-
ble by conducting 10 autonomic function
tests, which are thought to reﬂect all as-
pects of cardiovascular autonomic func-
tion. Previous cross-sectional studies
evaluating the relationship between mi-
croalbuminuria and C-AD used less ex-
tensive autonomic function tests (4,6).
Because we included all three groups of
GTS, we were able to analyze possible ef-
fect modiﬁcation of GTS in the relation-
ship between the main determinants,
C-AD and microalbuminuria and cardio-
vascular mortality (but found none).
There are several limitations to our
study. First, each of the test parameters of
autonomic function was measured with
moderate levels of reproducibility (reli-
abilitycoefﬁcient50%)(13).Therefore,
the results were combined into a C-AD
total score, which enabled us to circum-
vent, at least partially, this problem. Spe-
ciﬁcally, the results herein reported with
the C-AD total score were more powerful
than results obtained on the basis of each
individual test (separately), because these
results would be more strongly affected
bymisclassiﬁcation(likelytoberandom),
causing an underestimation of the
strength of the associations. Indeed, the
associations between each individual test
result with cardiovascular mortality were
in accordance, although with lower
strength, with those as reported herein
with the C-AD total score (data not
shown). In addition, this approach had
the advantage of circumventing the prob-
lem of multiple testing (type I errors) that
would have occurred when the associa-
tions with each test were analyzed sepa-
rately. However, because each test may
represent different parts of autonomic
function, some overlapping but others
complementary, our C-AD total score
does not allow the distinction of potential
different contributions of sympathetic
and parasympathetic functions to cardio-
vascular mortality. Therefore, we exam-
ined the autonomic function tests
combined on the basis of their methodol-
ogy or on the part of the autonomic ner-
vous system they predominantly
represent in the additional analyses. The
results of these alternative combinations
of autonomic function tests were compa-
rable to those of the C-AD total score
(supplementary Table A2), but we ac-
knowledge that these analyses may not
have been speciﬁc enough, as most au-
thors agree that a clear distinction be-
tween parasympathetic or sympathetic
dysfunction cannot be made on the basis
of these tests. Altogether, we feel that the
advantages (i.e., reduced misclassiﬁca-
tion and avoidance of type I errors with-
out impairment of etiological validity) of
Figure 1—Kaplan-Meier survival plots for cardiovascular mortality. Among individuals with normo- versus microalbuminuria (A) and across
tertiles of C-AD total score (B).
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advantages. Second, the spectral analyses
were performed during 3 min. Measure-
ment of HRV during a longer period may
be more reliable, although measurements
obtainedintimeperiodsasshortas2min
correlate highly with 24-h measurements
(25). Third, evaluation of subjects’ C-AD
was conducted at baseline only, and,
therefore, we were not able to evaluate
deterioration of autonomic function dur-
ing follow-up. Fourth, for most partici-
pants microalbuminuria was deﬁned on
an ACR measured in one urine sample
only. Because microalbuminuria is quite
variable from day to day we cannot fully
exclude the possibility that some subjects
were misclassiﬁed. However, we tried to
avoid this problem by collecting urine
overnight and expressing albumin excre-
tion as ACR. In addition, analyses in the
154 participants for whom two samples
were available yielded essentially similar
results(datanotshown).Finally,westud-
ied an elderly, Caucasian population, and
itisnotknownwhetherourresultscanbe
generalized to other ethnic groups or to
younger individuals.
In summary, we have shown that
both microalbuminuria and C-AD are in-
dependentlyassociatedwithcardiovascu-
lar mortality in an elderly, Caucasian
population of individuals with normal
glucose metabolism, IGM, and diabetes.
These results suggest that microalbumin-
uria and C-AD are related to cardiovascu-
lar mortality by different biological
pathways. Therefore, it may be useful to
treat not only microalbuminuria but also
C-AD in populations at high risk of car-
diovascular mortality.
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